Patient preferences for surgery and systemic therapy for tenosynovial giant cell tumor: a discrete choice experiment

Background Targeted therapies are increasingly available for locally aggressive, nonmalignant neoplasms, yet patient preferences remain poorly understood. Tenosynovial giant cell tumor (TGCT) is a locally aggressive mesenchymal neoplasm with multiple therapies and no consensus on frontline systemic treatment. Patients and methods This prospective observational study used a patient survey incorporating a discrete-choice experiment and rank-importance assessment, conducted by TGCT Support from January to March 2026. Treatment attributes included efficacy (tumor response, symptom improvement), adverse events (AEs), and convenience (route, dosing frequency), informed by literature and patient input. Relative importance and trade-offs were estimated using conditional regression models. Results A total of 250 patients were included (median age 46 years, 82.0% female, median disease duration 4.1 years). Patients reported, on average, 2.1 surgeries; 40.4% received systemic therapy (41.6% imatinib, 35.6% vimseltinib, and 31.7% pexidartinib) and 98% reported ≥1 AE, commonly fatigue (89.1%), facial/periorbital edema (64.4%), and pruritus (40.6%). For surgical outcomes, patients prioritized complete resection (54.0%) over symptom relief (34.4%). When complete macroscopic resection was unachievable, systemic therapy was strongly preferred. Among systemic therapies, symptom improvement was prioritized as an efficacy measure (60.4%). Patients preferred greater symptom relief ( P < 0.01), lower AE impact on quality of life (QoL; P < 0.01), and oral administration ( P = 0.04). Symptomatic improvement had the highest relative importance (49.3%), followed by fatigue (17.9%), tumor response (14.2%), and facial edema (11.2%). Patients required 1.9 times, 1.8 times, and 1.2 times the magnitude of the utility associated with the tumor response to offset invasive/disruptive treatment logistics, intravenous administration, and fatigue, respectively. Conclusions In TGCT, shared decision-making and regulatory considerations should prioritize symptoms while minimizing treatment burden and AE-related impacts on QoL.

Authors

Institutions

Publication Details

Journal
ESMO rare cancers.
Published
2026-11-17
DOI
https://doi.org/10.1016/j.esmorc.2026.100658
Primary Topic
Musculoskeletal synovial abnormalities and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Patient preferences for surgery and systemic therapy for tenosynovial giant cell tumor: a discrete choice experiment

Sara Rothschild, Sydney Stern, Gabriel Tinoco, Robin L. Jones et al.
3 links
ESMO rare cancers.
Musculoskeletal synovial abnormalities and treatments
article

Patient preferences for surgery and systemic therapy for tenosynovial giant cell tumor: a discrete choice experiment

Sara Rothschild, Sydney Stern, Gabriel Tinoco, Robin L. Jones, R.L. Randall, W.D. Tap, S. Stacchiotti, N.M. Bernthal, H.R. Abrams, C. Serrano
article en

Abstract

Background Targeted therapies are increasingly available for locally aggressive, nonmalignant neoplasms, yet patient preferences remain poorly understood. Tenosynovial giant cell tumor (TGCT) is a locally aggressive mesenchymal neoplasm with multiple therapies and no consensus on frontline systemic treatment. Patients and methods This prospective observational study used a patient survey incorporating a discrete-choice experiment and rank-importance assessment, conducted by TGCT Support from January to March 2026. Treatment attributes included efficacy (tumor response, symptom improvement), adverse events (AEs), and convenience (route, dosing frequency), informed by literature and patient input. Relative importance and trade-offs were estimated using conditional regression models. Results A total of 250 patients were included (median age 46 years, 82.0% female, median disease duration 4.1 years). Patients reported, on average, 2.1 surgeries; 40.4% received systemic therapy (41.6% imatinib, 35.6% vimseltinib, and 31.7% pexidartinib) and 98% reported ≥1 AE, commonly fatigue (89.1%), facial/periorbital edema (64.4%), and pruritus (40.6%). For surgical outcomes, patients prioritized complete resection (54.0%) over symptom relief (34.4%). When complete macroscopic resection was unachievable, systemic therapy was strongly preferred. Among systemic therapies, symptom improvement was prioritized as an efficacy measure (60.4%). Patients preferred greater symptom relief ( P < 0.01), lower AE impact on quality of life (QoL; P < 0.01), and oral administration ( P = 0.04). Symptomatic improvement had the highest relative importance (49.3%), followed by fatigue (17.9%), tumor response (14.2%), and facial edema (11.2%). Patients required 1.9 times, 1.8 times, and 1.2 times the magnitude of the utility associated with the tumor response to offset invasive/disruptive treatment logistics, intravenous administration, and fatigue, respectively. Conclusions In TGCT, shared decision-making and regulatory considerations should prioritize symptoms while minimizing treatment burden and AE-related impacts on QoL.

ESMO rare cancers.Vol. 8
Hebron University (PS), Memorial Sloan Kettering Cancer Center (US), Institute of Cancer Research (GB), University of California, Los Angeles (US), University of Washington (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Fred Hutch Cancer Center (US), Royal Marsden Hospital (GB), Vall d'Hebron Hospital Universitari (ES), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), University of California Davis Medical Center (US), Life Raft Group (US), Vall d'Hebron Institute of Oncology (ES), University of California, Davis (US)
Deciphera Pharmaceuticals, EMD Serono
Good health and well-being
Musculoskeletal synovial abnormalities and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon